One lot of thyroid tablets was pulled nationwide after tests flagged “superpotent” pills that can push patients into hyperthyroidism.
Story Snapshot
- Vitruvias recalled one lot of 30 mg thyroid tablets at the consumer level.
- Tests found potential for superpotency, which can trigger hyperthyroid symptoms.
- The affected lot is 504950, NDC 69680-166-00, with a 9/30/2026 expiration.
- The company reported no related adverse events at the time of the notice.
The Recall: What, Who, and How Many
Vitruvias Therapeutics announced a nationwide recall of one lot of Thyroid Tablets, United States Pharmacopeia 30 milligrams, after testing confirmed the potential for superpotency. The affected lot is 504950, tied to National Drug Code 69680-166-00, with an expiration date of September 30, 2026.
The company distributed 3,655 units and sold 1,955 units to direct accounts between January 31, 2025, and September 30, 2025, across the United States. The recall is at the consumer level, which means patients should check their bottles.
'Superpotent' Thyroid medication recalled one month after FDA advises against similar tablets https://t.co/jGK75IOEcX pic.twitter.com/jhFrWTCro8
— New York Post (@nypost) August 25, 2026
USA Today reported the same identifiers, reinforcing which bottles to look for on home shelves and pharmacy stock. Patients who find lot 504950 should stop using it and follow the recall instructions from the notice or their pharmacy.
The Food and Drug Administration recall process aims to remove affected units fast, then verify the reach of the action through effectiveness checks. That back-end work matters when thousands of units may already be with patients.
Why Superpotency Matters With Thyroid Hormone
Thyroid hormone has a narrow target range. Too little leaves you sluggish. Too much speeds up the body and can strain the heart.
Superpotent thyroid tablets can cause hyperthyroidism, with symptoms like weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and rhythm problems.
Older adults and people with heart disease face higher risk from sudden excess hormone. That is why even a single-lot recall deserves swift attention.
The Food and Drug Administration has seen potency errors before, both “too strong” and “too weak.” Thyroid medicines show up in recall data because small potency shifts can change how patients feel and how their hearts perform.
In prior thyroid recalls, other firms disclosed measured overages up to 115 percent of the labeled amount, a level that can tip stable patients into symptoms. The pattern shows routine testing can catch problems before injury reports arrive, which is the goal.
What To Do If You Have This Lot
Check your bottle’s lot and National Drug Code on the label. If it reads lot 504950 and National Drug Code 69680-166-00, stop taking it and contact your pharmacy for guidance on returns and replacement.
Call your prescriber about next steps, especially if you have chest pain, palpitations, shortness of breath, or sudden anxiety. Keep a simple log of any new symptoms and your resting heart rate. If you have severe chest pain or feel faint, seek urgent care. Common sense says act fast and steady, not scared.
Recall: Vitruvias Thyroid Tablets USP 30 mg — lot 504950, exp. 9/30/2026, NDC 69680-166-00 — for potential superpotency.
Check your bottle. If it matches, contact your pharmacy or clinician. Do not discontinue without clinician guidance.https://t.co/rRHBYf0Ump
— The Modern Bio (@themodernbio) August 26, 2026
Vitruvias reported no adverse events tied to this recall at the time of the notice, which suggests the alert is precautionary and aimed at preventing harm. That is the system working.
The smarter play is to swap unsafe tablets quickly and monitor patients rather than wait for the first heart scare to show up in the emergency room. Pharmacies can help check inventory and patient profiles and can often arrange exchanges without delay.
How This Fits the Bigger Drug-Safety Picture
Drug recalls happen most often for quality issues, and potency errors are a leading slice of those problems. Thyroid tablets sit in the spotlight because doctors titrate doses in small steps and watch lab results closely.
A superpotent pill can cloud that picture and nudge a stable patient off track. The Food and Drug Administration’s recall log lists potency-related actions across many drug types, which shows the need for tight controls and steady oversight from factory to pharmacy shelf.
Sources:
nypost.com, fda.gov, usatoday.com, passionhealthphysicians.com, thehill.com
